Targets for improving prostate tumor response to radiotherapy

Area of Science:

• Oncology
• Radiotherapy Research
• Molecular Biology

Background:

• Prostate cancer (PCa) management often involves radiotherapy, but radioresistance limits treatment efficacy.
• Therapeutic strategies for recurrent and metastatic castration-resistant prostate cancer (mCRPC) include late-stage radiotherapy and combination therapies.
• Severe toxicities from combined radiotherapy and chemotherapy necessitate strategies for selective tumor sensitization.

Purpose of the Study:

• To review potential targets for sensitizing prostate tumors to radiotherapy.
• To discuss the multifaceted mechanisms of radioresistance in prostate cancer.
• To examine experimental and clinical findings on promising combination therapies.

Main Methods:

• Review of literature on prostate cancer radioresistance mechanisms.
• Analysis of cellular and molecular pathways contributing to therapy resistance.
• Examination of clinical trial data for novel therapeutic targets and drugs.

Main Results:

• Prostate cancer radioresistance involves complex pathways including DNA damage repair, hypoxia, angiogenesis, androgen receptor signaling, and immune evasion.
• Emerging therapies like 177Lu-PSMA-617 show promise for advanced prostate cancer.
• Combination therapies integrating radiotherapy with novel agents targeting resistance pathways demonstrate enhanced efficacy in preclinical and clinical studies.

Conclusions:

• Selective sensitization of prostate tumors to radiotherapy can improve treatment outcomes and minimize systemic toxicities.
• Targeting specific resistance mechanisms offers a promising avenue for enhancing radiotherapy effectiveness in prostate cancer.
• Further research into combination strategies holds potential for overcoming radioresistance and improving patient survival.